Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis

Summary

The objective of the study is to demonstrate the superiority of the mesoglycan (Prisma®), compared to placebo, in reducing the incidence of thromboembolic complications (relapse / extension of superficial venous thrombosis (SVT), deep venous thrombosis (DVT), pulmonary embolism (PE)) in patients who have completed the cycle of therapy of the acute phase after superficial vein thrombosis.

Timeline

Start

2018-03-26

Primary completion

2024-12-31

Completion

2024-12-31

Publications

• Camporese G, Bernardi E, Bortoluzzi C, Noventa F, Simioni P; METRO Investigator Study Group. Mesoglycan for the secondary prevention of superficial vein thrombosis: a randomized, controlled, double-blind study (METRO Study)-rationale and protocol. J Thromb Thrombolysis. 2024 Feb;57(2):226-234. doi: 10.1007/s11239-023-02896-6. Epub 2023 Nov 6.

Drugs

Indications